Good Lifestyle

The recent increase in the popularity of weight loss drugs such as Wegovy - as well as the Diabetes Ozempic drugs which is prescribed excluding label for weight loss - approaches what could be a transformer moment in How people lose books . Unfortunately, the potentially changing drugs that change their life have also been prevented from going to some who may need it most by high costs and supply problems. But now, the new Zepbound weight loss medication has hit American pharmacies, which could potentially help reduce certain problems in the midst of an ozempic shortage. Read the rest to see how the arrival of the very effective medication could affect the prescriptions.

In relation: A whole new medication reverses obesity without real side effects, say the researchers .

The booming market of weight loss medication has become a little more robust. December 4, Pharmaceutical company Eli Lilly announced that his new medication, Zepbound, is available in American pharmacies. AE0FCC31AE342FD3A1346EBB1F342FCB

The prescription weight loss medication is taking shelves about a month after the US Food & Drug Administration (FDA) has made its approval . Previously, the drug - which is called Tirzepatide - was available on the market like Mounjaro but was only approved for Treat type 2 diabetes In adults, reports CNN.

According to the company's press release, Zepbound may be prescribed for adults with obesity, whose body mass index (BMI) judges them overweight, or who suffer from health problems, including the 'Hypertension, type 2 diabetes, sleep apnea, or heart disease.

In relation: Lose 50 pounds by following 2 simple rules, success .

The arrival of Zepbound also comes at a time when similar drugs are faced with a tight shortage. THE downwards Unfortunately left some that rely on drugs for serious health reasons.

"In the past three to four months, patients have told me that they cannot get [Mounjaro]" Jody Dushay , MD, clinical endocrinologist at Beth Israel Deaconess Medical Center in Boston, told CNN in October. "I am aware of our supply literally on a daily basis."

On November 27, the manufacturer of Wegovy and Ozempic, Novo Nordisk, also announced that he Start the starter dosage kits From Ozempic in Europe in the midst of a supply crisis, Reuters reported. The company also said that it would start to reduce the supplies of its Diabetes Victoza drug so that it can allocate resources to the production of more from its successful counterpart.

In relation: The ozempic patient reveals "a new" atrocious "side effect .

The arrival of shooting with a wider set of approved uses could help to reduce some of the current storage problems for pharmacies. But others also hope that this could help reduce weight loss drugs in general. In her initial approval announcement, Eli Lilly said she would set the Zepbound market price to About $ 1,060 per month - which is 20% lower than the monthly price label of $ 1,349 for Wegovy, according to Fortune .

For some insurance plans, the price of the medication could drop as low as $ 25 per month. And those whose insurance does not cover drugs could also be eligible for a company's assistance program which reduces the cost by half to $ 550 per month.

"Today opens another chapter to adults living with obesity that is looking for a new treatment option like Zepbound", " Rhonda Pacheco , Vice-President of Eli Lilly diabetes and obesity in the United States, the company's press release said. "Zepbound's availability in American pharmacies is the first step, but we have to work hand in hand with employers, government and health care industry to eliminate obstacles and make Zepbounds available to Those who need it. "

In relation: Weightwatchers apologize to customers while pivoting weight loss drugs: "We were wrong."

In addition to hoping to increase availability, Zepbound has also proven to be an effective option for losing weight. Clinical trials have revealed that patients taking higher doses of the drug saw 20% average weight loss in more than 72 weeks, placing it higher than its competitors, reports CNN.

However, patients have prescribed that drugs could also cope with certain side effects. The FDA has listed gastrointestinal problems such as "nausea, diarrhea, vomiting, constipation, discomfort and abdominal pain (stomachs)" as the most common. The manufacturer also includes warnings for other potentially serious side effects on the Zepbound label, in particular pancreatitis, the problems of the gallbladder, low blood sugar, potential vision problems for people with type 2 diabetes , kidney problems and depression or suicidal thoughts.

Best Life offers the most up -to -date information for high -level experts, new research and health agencies, but our content is not supposed to replace professional advice. Regarding the medication you take or any other health issue you have, always consult your health care provider directly.

In relation: For more information, register for our daily newsletter .